Skip to main content

Table 3 Neuromuscular blockade, train-of-four (TOF) measurements, and intensive care unit-acquired weakness (ICU-AW) 7 days after awaking

From: Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study

 

ICU-AW = Yes

ICU-AW = No

p value

Whole population

N = 14

N = 33

 

 Measures of facial TOF = 0/all measures of facial TOF

75/147 (51%)

97/243 (40%)

0.03

 Measures of ulnar TOF = 0/all measures of ulnar TOF

111/147 (76%)

151/243 (62%)

0.006

Center 1

N = 12

N = 29

 

 Cisatracurium total dose (mg)

1482 (635–3257)

998 (591–1470)

0.25

 Cisatracurium duration (h)

89 (42–210)

65 (35–110)

0.28

Center 2

N = 2

N = 4

 

 Atracurium total dose (mg)

1056 (1092–1320)

472 (418–749)

0.06

 Atracurium duration (h)

190 (186–195)

93 (76–105)

0.07

  1. Continuous variables are reported as medians and interquartile ranges (25th–75th percentiles)
  2. ICU-AW intensive care unit-acquired weakness, NMBAs neuromuscular blocking agents, TOF train of four